Law.com Subscribers SAVE 30%

Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.

Drug & Device News

FDA Says Class of Strong Antibiotics Should Be Used Sparingly

On July 26, the U.S. Food and Drug Administration (FDA) announced increased safety labeling requirements for a class of antibiotics called fluoroquinolones. These types of antibiotics ' including levofloxacin (Levaquin), ciprofloxacin (Cipro), ciprofloxacin extended-release tablets, moxifloxacin (Avelox), ofloxacin and gemifloxacin (Factive) ' are used for treating severe bacterial infections. However, they come with serious potential side-effects, such as muscle, joint and nerve damage. According to the FDA, these side-effects may show up hours or days after the drugs are taken, and their effects can be permanent. Because of this, the agency advised against the use of fluoroquinolones for garden-variety infections such as acute bacterial sinusitis, acute exacerbation of chronic bronchitis and uncomplicated urinary tract infections. Instead of reaching immediately for these stronger medications, the FDA says they should be used only when other treatments will not work ' the examples offered being anthrax, plague and bacterial pneumonia.

'

First Head Trauma Cognitive Deficit Assessment Devices Approved for Marketing

Each year, more than 2 million people sustain head injuries that require a trip to the Emergency Room, according to the U.S. Centers for Disease Control and Prevention. Of these, around 50,000 die, and many more suffer short- and long-term cognitive deficits. In August, the FDA approved two devices that will allow medical practitioners to assess the presence and extent of traumatic brain injury in head trauma victims. These products ' the Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) and ImPACT Pediatric ' are the first devices the FDA has permitted to be marketed for this purpose. They run on desktop or laptop computers and test cognitive skills like reaction time and word recognition. Results are compared to the head injury victim's pre-injury baseline scores, or to an age-matched control database if no patient-specific results are available.

Carlos Pe'a, the director of the division of neurological and physical medicine devices at the FDA's Center for Devices and Radiological Health, cautions, however that while these devices provide “a useful new tool to aid in the evaluation of patients experiencing possible signs of a concussion, but clinicians should not rely on these tests alone to rule out a concussion or determine whether an injured player should return to a game.”

'

All Blood Should Be Tested for Zika Virus, Agency Says

The FDA is recommending that all donated whole blood and blood products be tested for the Zika virus. “There is still much uncertainty regarding the nature and extent of Zika virus transmission,” said Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research in an Aug. 26 FDA release. See http://bit.ly/2cCL9KQ. Marks continued, “At this time, the recommendation for testing the entire blood supply will help ensure that safe blood is available for all individuals who might need transfusion.” The Zika outbreak, which at first was mostly limited to countries in South America or to people who had traveled there, showed up late last year in Puerto Rico, and has now been documented in people in South Florida who have not recently traveled. Zika is most often contracted through the bite of the Aedes mosquito, but can also be transmitted through sexual contact. The virus causes uncomfortable symptoms, such as fever and joint pain, but its worst effect is on unborn children, who can develop serious birth defects when their mothers are infected during pregnancy.

'

This premium content is locked for Entertainment Law & Finance subscribers only

  • Stay current on the latest information, rulings, regulations, and trends
  • Includes practical, must-have information on copyrights, royalties, AI, and more
  • Tap into expert guidance from top entertainment lawyers and experts

For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473

Read These Next
Strategy vs. Tactics: Two Sides of a Difficult Coin Image

With each successive large-scale cyber attack, it is slowly becoming clear that ransomware attacks are targeting the critical infrastructure of the most powerful country on the planet. Understanding the strategy, and tactics of our opponents, as well as the strategy and the tactics we implement as a response are vital to victory.

'Huguenot LLC v. Megalith Capital Group Fund I, L.P.': A Tutorial On Contract Liability for Real Estate Purchasers Image

In June 2024, the First Department decided Huguenot LLC v. Megalith Capital Group Fund I, L.P., which resolved a question of liability for a group of condominium apartment buyers and in so doing, touched on a wide range of issues about how contracts can obligate purchasers of real property.

CoStar Wins Injunction for Breach-of-Contract Damages In CRE Database Access Lawsuit Image

Latham & Watkins helped the largest U.S. commercial real estate research company prevail in a breach-of-contract dispute in District of Columbia federal court.

The Article 8 Opt In Image

The Article 8 opt-in election adds an additional layer of complexity to the already labyrinthine rules governing perfection of security interests under the UCC. A lender that is unaware of the nuances created by the opt in (may find its security interest vulnerable to being primed by another party that has taken steps to perfect in a superior manner under the circumstances.

Fresh Filings Image

Notable recent court filings in entertainment law.